Encounter for antineoplastic chemotherapy. Z51.11 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2019 edition of ICD-10-CM Z51.11 became effective on October 1, 2018.
The new codes are for describing the infusion of tixagevimab and cilgavimab monoclonal antibody (code XW023X7), and the infusion of other new technology monoclonal antibody (code XW023Y7).
Search the full ICD-10 catalog by:
The ICD-10-CM is a catalog of diagnosis codes used by medical professionals for medical coding and reporting in health care settings. The Centers for Medicare and Medicaid Services (CMS) maintain the catalog in the U.S. releasing yearly updates.
2022 ICD-10-PCS Codes 3E04*: Central Vein.
Report ICD-10 code Z01. 818, Encounter for other preprocedural examination (is defined as Encounter for preprocedural examination NOS and Encounter for examinations prior to antineoplastic chemotherapy), when the test is performed as a baseline study before chemotherapy. List Z01. 818 as your primary diagnosis code.
ICD-10 Code for Other long term (current) drug therapy- Z79. 899- Codify by AAPC.
Encounter for antineoplastic chemotherapy Z51. 11 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM Z51. 11 became effective on October 1, 2021.
Code 96413 (chemotherapy administration, intravenous infusion technique; up to one hour, single or initial substance/drug) would be used to report the first 90 minutes of the infusion.
You can only bill for chemotherapy administration if you own the facility. If it is a hospital–based infusion center, you cannot collect for chemo administration.
ICD-10-CM Code for Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter T45. 1X5A.
Antineoplastic drugs are medications used to treat cancer. Other names for antineoplastic drugs are anticancer, chemotherapy, chemo, cytotoxic, or hazardous drugs.
The ICD-10 section that covers long-term drug therapy is Z79, with many subsections and specific diagnosis codes. Because Plaquenil does not have its own specific category, clinicians should use Z79. 899—Other Long Term (Current) Drug Therapy.
If a patient admission/encounter is solely for the administration of chemotherapy, immunotherapy or external beam radiation therapy assign code Z51.
When a primary malignancy has been previously excised or eradicated from its site and there is no further treatment directed to that site and there is no evidence of any existing primary malignancy at that site, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy. Any mention of extension, invasion, or metastasis to another site is coded as a secondary malignant neoplasm to that site. The secondary site may be the principal or first-listed with the Z85 code used as a secondary code.
There are also codes Z85.6, Personal history of leukemia, and Z85.79, Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues. If the documentation is unclear as to whether the leukemia has achieved remission, the provider should be queried.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion '), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous such as tumors in different quadrants of the same breast, codes for each site should be assigned.
Chapter 2 of the ICD-10-CM contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms , such as prostatic adenomas, may be found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant, or of uncertain histologic behavior. If malignant, any secondary ( metastatic) sites should also be determined.
Code C80.0, Disseminated malignant neoplasm, unspecified, is for use only in those cases where the patient has advanced metastatic disease and no known primary or secondary sites are specified. It should not be used in place of assigning codes for the primary site and all known secondary sites.
When a pregnant woman has a malignant neoplasm, a code from subcategory O9A.1 -, malignant neoplasm complicating pregnancy, childbirth, and the puerperium, should be sequenced first, followed by the appropriate code from Chapter 2 to indicate the type of neoplasm. Encounter for complication associated with a neoplasm.
Code C80.1, Malignant ( primary) neoplasm, unspecified, equates to Cancer, unspecified. This code should only be used when no determination can be made as to the primary site of a malignancy. This code should rarely be used in the inpatient setting.
Question: When coding the placement of an infusion device such as a peripherally inserted central catheter (PICC line), the code assignment for the body part is based on the site in which the device ended up (end placement). For coding purposes, can imaging reports be used to determine the end placement of the device?
Question: ...venous access port. An incision was made in the anterior chest wall and a subcutaneous pocket was created. The catheter was advanced into the vein, tunneled under the skin and attached to the port, which was anchored in the subcutaneous pocket. The incision was closed in layers.
Question: In Coding Clinic, Fourth Quarter 2013, pages 116- 117, information was published about the device character for the insertion of a totally implantable central venous access device (port-a-cath). Although we agree with the device value, the approach value is inaccurate.
Question: A patient diagnosed with Stage IIIC ovarian cancer underwent placement of an intraperitoneal port-a-catheter during total abdominal hysterectomy. An incision on the costal margin in the midclavicular line on the right side was made, and a pocket was formed. A port was then inserted within the pocket and secured with stitches.
Question: The patient has a malfunctioning right internal jugular tunneled catheter. At surgery, the old catheter was removed and a new one placed. Under ultrasound guidance, the jugular was cannulated; the cuff of the old catheter was dissected out; and the entire catheter removed.